SCHEMBL6288797

SCHEMBL6288797

O=C(O)c1cc2cc(Cc3ccc(F)c(F)c3)cnc2s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
KDM5A P29375 1/20 0.40
KDM5B Q9UGL1 1/20 0.40
S1PR1 P21453 3/20 0.39
S1PR3 Q99500 2/20 0.39
TBXAS1 P24557 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GLA P06280 1/20 0.38
PKM P14618 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PDE5A O76074 2/20 0.37
VNN1 O95497 1/20 0.36
BCL2L1 Q07817 1/20 0.36
MAOB P27338 1/20 0.36
FYN P06241 1/20 0.36
JAK2 O60674 1/20 0.36
ZAP70 P43403 1/20 0.36
SYK P43405 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6289393 0.73 KDM5A (0.40) MEN1KMT2AKDM5AKDM5BS1PR1
SCHEMBL6288962 0.73 S1PR1 (0.36) S1PR1S1PR3JAK2ZAP70SYK
SCHEMBL6289350 0.72 KDM5A (0.45) KDM5AKDM5BS1PR1S1PR3TBXAS1
SCHEMBL16557145 0.70 MEN1 (0.44) MEN1KMT2AKDM4EALDH1A1GLA
SCHEMBL6289345 0.69 MAOB (0.55) S1PR1S1PR3L3MBTL1MAOBCACNA1G
SCHEMBL6292130 0.69 HDAC1 (0.51)
SCHEMBL6288754 0.69 KDM5A (0.39) KDM5AKDM5BS1PR1S1PR3VNN1
SCHEMBL6292695 0.68 HDAC1 (0.48)
SCHEMBL25409122 0.68 ALDH1A1 (0.44) MEN1KMT2ATBXAS1KDM4EALDH1A1
SCHEMBL32686064 0.68 ALDH1A1 (0.44) MEN1KMT2AKDM4EALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949651-B2 Fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-09-27 US claimed
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors LINCOLN FOODSERVICE PRODUCTS INC. 2004-02-19 US claimed
WO-2004014375-A2 FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-6949651-B2 Fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-09-27 US disclosed
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors LINCOLN FOODSERVICE PRODUCTS INC. 2004-02-19 US disclosed
WO-2004014375-A2 FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 MEN1 2588/4885KMT2A 2273/4885KDM5A 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.